IDEXX Laboratories is seeing a positive uptick in its stock price, driven by strong growth projections and innovative diagnostic solutions.
IDEXX Laboratories Inc (NASDAQ:IDXX) is rising today, with shares up by 1.56% to close at CA$523.35. This movement comes on the heels of reaffirmed long-term growth targets and an innovative diagnostic pipeline that positions the company favorably in the veterinary diagnostics market.
Investor takeaway: Investors are encouraged by IDEXX's commitment to innovation and growth, despite challenges in veterinary visit volumes. The company's focus on expanding its diagnostic offerings could drive long-term value.
Advertisement
IDEXX Laboratories Inc
IDXX.US
IDXX.US
IDEXX Laboratories Inc
WealthAwesomeMarket cap
$40.31B
P/E
36.0x
52W high
$769.98
52W low
$500.61
1W change
+1.13%
Beta
1.54
Analyst Price Targets
Based on 13 analysts covering IDXX · as of Sep 17, 2026
Wall Street analysts forecast IDXX stock price to rise 35.6% over the next 12 months.
Consensus
Buy3.62 / 5.00
Avg. Target
C$698.92
+35.6% Upside
Current Price
C$515.30
Last close
Analyst Breakdown (13 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IDXX's historical volatility
30-Day Vol
24.6%
Annualized
90-Day Vol
29.1%
Annualized
Trend (90d)
-31.1%
Annualized drift
90d Mean
C$461.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$496.55 | C$456.14 – C$540.55 |
| 60 trading days | C$478.49 | C$424.36 – C$539.52 |
| 90 trading days | C$461.09 | C$398.04 – C$534.11 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
1.56% Increase in Stock Price
IDEXX's stock price increase reflects investor confidence in its growth strategy and the potential of its diagnostic innovations.
Bull case
IDEXX's strong growth outlook is backed by a large, underpenetrated market and a solid pipeline of diagnostic innovations. This positions the company well for long-term revenue and earnings growth. Its focus on recurring revenue and expanding product offerings supports sustained growth.
Bear case
Despite the positive outlook, IDEXX is facing challenges from declining veterinary visits, especially in wellness care. If these trends continue, they could affect the company's growth and investor sentiment.
Strong Growth Projections
Advertisement
IDEXX Laboratories has reaffirmed its long-term growth targets, aiming for more than 10% organic revenue growth and over 15% earnings-per-share growth. This is supported by a large, underpenetrated veterinary diagnostics market and strong recurring revenue momentum. The company continues to benefit from an aging pet population and increased medicalization.
Innovative Diagnostic Pipeline
The company is focusing on expanding its diagnostic offerings, including the inVue Dx cytology platform and the rollout of Cancer Dx tests. IDEXX's commitment to innovation is expected to drive further growth in its reference laboratory and VetLab recurring revenue streams, positioning the company well in a competitive market.
Challenges Ahead
Despite the positive outlook, IDEXX faces challenges with a projected decline in veterinary visits, particularly in wellness care. The company anticipates a 1.5% decline in visits during the second half of the year. Investors will need to monitor these trends closely to assess their potential impact on the company's growth trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
